KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Non-Current Debt (2016 - 2025)

NovoCure (NVCR) has disclosed Non-Current Debt for 11 consecutive years, with $195.0 million as the latest value for Q4 2025.

  • Quarterly Non-Current Debt rose 100.46% to $195.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $195.0 million through Dec 2025, up 100.46% year-over-year, with the annual reading at $195.0 million for FY2025, 100.46% up from the prior year.
  • Non-Current Debt hit $195.0 million in Q4 2025 for NovoCure, roughly flat from $194.6 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $569.7 million in Q1 2024 to a low of $97.0 million in Q2 2024.
  • Historically, Non-Current Debt has averaged $402.5 million across 5 years, with a median of $561.4 million in 2021.
  • Biggest five-year swings in Non-Current Debt: skyrocketed 274.94% in 2021 and later crashed 82.9% in 2024.
  • Year by year, Non-Current Debt stood at $562.2 million in 2021, then increased by 0.59% to $565.5 million in 2022, then rose by 0.44% to $568.0 million in 2023, then plummeted by 82.87% to $97.3 million in 2024, then soared by 100.46% to $195.0 million in 2025.
  • Business Quant data shows Non-Current Debt for NVCR at $195.0 million in Q4 2025, $194.6 million in Q3 2025, and $97.6 million in Q2 2025.